The Senate Judiciary Committee next Thursday (Sept. 19) will mark up bipartisan bills that would reform the rules and procedures a tribunal under the United States Patent and Trademark Office must adhere to when reviewing patent validity and would restore patent eligibility to various inventions across multiple fields -- a move that has sparked strong objections from a drug-price reform advocacy group, which says the bills could to lead to higher prices.